Risk of cardiovascular disease in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2009, Pages 386-389

  Das, Satyajit ^a  

^a Department of Rehabilitation Services   (United Kingdom)

Author keywords

Abacavir; Adverse drug reactions; Antiretrovirals; Lipids; Toxicities; Viral replications

Indexed keywords

ABACAVIR; C REACTIVE PROTEIN; D DIMER; DIDANOSINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFLAMMATION; ISCHEMIC HEART DISEASE; RISK FACTOR; SMOKING; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 77950311564     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp460     Document Type: Article

References (23)

1. Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-12.
2. Klein D, Hurley LB, Quesenberry CP et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-7.
3. Triant VA, Lee H, Hadigan C. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
4. Lundgren J, Reiss P, Worm S et al. Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: the DAD study. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 44LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
5. Lang S, Mary-Krause M, Cotte L et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 43LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
6. Lichtenstein KA, Buchacz K, Moorman A et al. Analysis of cardiovascular risk factors in the HIV Outpatient Study (HOPS) cohort. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 135. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
7. Phillips AN, Carr A, Neuhaus J et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177-87.
8. El-Sadr WM, Grund B, Neuhaus J et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149: 289-99.
9. Grunfeld C, Delaney J, Wanke C et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23: 1841-9.
10. Vigano A, Patterino G, Cerini C et al. What happens to children growing up with HIV infection? It's time for a HAART to heart. Expert Rev Anti Infect Ther 2009; 7: 495-8.
11. Tebas P, Henry WK, Matining R et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE 2008; 3: e2021.
12. Kuller L, SMART Study Group. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 139. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
13. Durand M, Sheehy O, Baril J-G et al. Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID). In: Abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract TUPEB175.
14. Benson C, Ribaudo H, Zheng E et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 721. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
15. Brothers CH, Hernandez JE, Cutrell AG et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-8.
16. Bedimo R, Westfall A, Drechsler H et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. In: Abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract MOAB202.
17. Cooper D, Bloch M, Humphries A et al. Simplification with fixed-dose tenofovir/emtricitabine or abacavir/lamivudine in adults with suppressed HIV replication: the STEAL study, a randomized, open-label, 96-week, non-inferiority trial. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 576. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
18. Costagliola D. The current debate on abacavir; risks and relationship between HIV viremia and cardiovascular events. In: Abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Invited lecture MOAB201.
19. Satchell C, O'Connor E, Peace A et al. Platelet hyper-reactivity in HIV-1-infected patients on abacavir-containing ART. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 151LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
20. Hsue P, Wu Y, Schnell A et al. Association of abacavir and HIV disease factors with endothelial function in patients on long-term suppressive ART. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 723. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
21. McComsey G, Smith K, Patel P et al. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/ lamivudine or tenofovir/emtricitabine: the HEAT study. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 732. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
22. Martinez E, Larrousse M, Perez I et al. No evidence for recent abacavir/ lamivudine use in promoting inflammation, endothelial dysfunction, hypercoagulability, or insulin resistance in virologically suppressed HIV-infected patients: a substudy of the BICOMBO randomized clinical trial (ISRCTN6189). In: Abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract MOAB202.
23. Baum MK, Rafie C, Sales S et al. C-reactive protein: a poor marker of cardiovascular disease risk in HIV{thorn} populations with a high prevalence of elevated serum transaminases. Int J STD AIDS 2008; 19: 410-3.